1IJA Stock Overview
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Adicet Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.28 |
| 52 Week High | US$6.80 |
| 52 Week Low | US$0.92 |
| Beta | 1.62 |
| 1 Month Change | -37.41% |
| 3 Month Change | -52.91% |
| 1 Year Change | -78.40% |
| 3 Year Change | -89.08% |
| 5 Year Change | n/a |
| Change since IPO | -90.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1IJA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -21.4% | 2.1% | -1.0% |
| 1Y | -78.4% | -22.2% | 2.0% |
Return vs Industry: 1IJA underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 1IJA underperformed the German Market which returned 2% over the past year.
Price Volatility
| 1IJA volatility | |
|---|---|
| 1IJA Average Weekly Movement | 11.1% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1IJA's share price has been volatile over the past 3 months.
Volatility Over Time: 1IJA's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 143 | Chen Schor | www.adicetbio.com |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Adicet Bio, Inc. Fundamentals Summary
| 1IJA fundamental statistics | |
|---|---|
| Market cap | €110.67m |
| Earnings (TTM) | -€132.52m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.8x
P/E RatioIs 1IJA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1IJA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$142.66m |
| Earnings | -US$142.66m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.74 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 1IJA perform over the long term?
See historical performance and comparison